ALSO NOTED: Pantec raises $5.67 for drug delivery work; Medarex gets milestone payment; and much more...

> You can take your $4 million and keep it. David Stout (photo), GlaxoSmithKline's president of pharmaceutical operations, evidently wants no part of the reported $4 million incentive package he was offered after being passed up for the top job. Report

> Pantec Biosolutions, a drug delivery company specializing in laser micro-poration technology for the transdermal delivery of large molecular weight drugs, has announced the successful initiation of its Series A equity investment round raising $5.67 million. Report

> Florida-based Catalyst Pharmaceutical is reporting positive Phase II results for vigabatrin for the treatment of cocaine addiction. Catalyst's lead compound, CPP-109, is bioequivalent to vigabatrin. Release

> Medarex will receive an undisclosed milestone payment from J&J's Centocor for the FDA submission of ustekinumab (CNTO 1275). Ustekinumab is an experimental drug for chronic moderate to severe plaque psoriasis. Release

> Cancer specialist and FDA advisory panel member Aman Buzdar cast one of the 'no' votes against Genentech's Avastin, which failed to measure up in extending survival times of breast cancer patients. Report

> Medicare took a look at what they say hospitals have been paying for the new biologics that treat non-Hodkin's lymphoma and decided to slash what it will pay for Bexxar and Zevalin to $16,000 per treatment. That may sound like a lot, but it's only slightly more than half of the companies' sticker price. Report

> A group of IT and pharma-related companies has begun lobbying for changes in the rules around controlled drugs which would allow physicians to prescribe them electronically. Report

And Finally... The next cancer-fighting therapeutic could be growing in your garden. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.